MDR transition delay approved by European Parliament and Council

EU Commissioner for Health and Food Safety Stella Kyriakides [Photo courtesy of the European Commission]

The European Parliament and Council today voted to approve a Medical Devices Regulation (MDR) transition delay in an effort to avoid shortages.

The move gives medical device manufacturers more time to certify their devices under the new MDR rules.

“I welcome today’s [European Parliament] vote to extend the transition period to new rules under the Medical Devices Regulation,” Commissioner for Health and Food Safety Stella Kyriakides said. “This will help give clarity to manufacturers and ensure that patients can access the essential medical devices they need. This is our top priority.”

The delay does not modify MDR’s current safety and performance requirements. Instead, it gives manufacturers more time to move from the old rules to the new requirements.

It al…

Read more
  • 0

European Commission endorses MDR transition delay

EU Commissioner for Health and Food Safety Stella Kyriakides [Photo courtesy of the European Commission]

An MDR transition delay is one step closer to reality following concerns that the current timeline could lead to medical device shortages.

The European Commission on Jan. 6 officially endorsed a proposal to give medical device manufacturers more time to certify their devices under new Medical Devices Regulation (MDR) rules. The proposed MDR transition delay will not become official without approval by the European Parliament and Council.

The proposal would not change any of MDR’s current safety and performance requirements. Instead, it would give manufacturers more time to move from the old rules to the new requirements. It would remove the “sell-off” date and extend transition periods.

RELATED: Navigating MDR’s newly charted waters

MDR went into effect in May 2021 with…

Read more
  • 0

Janssen gets positive CHMP opinion for Imbruvica for adults with untreated chronic lymphocytic leukemia

Janssen (NYSE:JNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Imbruvica (ibrutinib) with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukemia (CLL).

In the EU, the drug is also indicated for certain patients with mantle cell lymphoma, previously treated chronic lymphocytic leukemia and Waldenström’s macroglobulinemia, also known as lymphoplasmacytic lymphoma.

CHMP’s recent positive opinion was based on the Phase 3 GLOW and Phase 2 CAPTIVATE studies.

Janssen noted in a press release that if the new indication is approved, Imbruvica will be the first oral, once-daily, fixed-duration, combination regimen for first-line treatment of CLL.

Janssen developed the drug with Pharmacyclics LLC, an AbbVie company.

Imbruvica is a Bruton’s tyrosine kinase inhibitor. Venetoclax is an apoptosis stimulant and proto…

Read more
  • 0